"Ultimately, long-term studies are vital to parse out whether the absence of iodinated contrast media greatly affected patient outcomes or if we have been overdependent on ICM unnecessarily.” 

Bracco Diagnostics, Inc has been given the go ahead by the U.S. Food and Drug Administration to temporarily import Iomeron (iomeprol injection) into the U.S. market amid the ongoing iodinated contrast media shortage. 

“For patients with a prior ICM-induced hypersensitivity reaction, healthcare providers must balance the benefit of ICM reuse against the risk of a repeat reaction,” authors of a new meta-analysis published in Radiology said.

On July 18 Fresenius Kabi announced that they are rolling out a line of generic contrast media products, starting immediately with Iodixanol Injection USP. 

Per Bayer’s communications, the contrast agent is manufactured at the same site in Berlin, Germany as the Ultravist that is intended for U.S. markets, but due to its intended distribution abroad it lacks current FDA-approved labeling. 

GE previously indicated that the iodinated contrast shortage would resolve by the end of June.

Beyond readmission, 32.9% of patients with increased pancreatic necrosis volumes required additional invasive interventions.

Such assessments could “decrease existing diagnosis gaps,” according to a new study published in Academic Radiology.